|
(一)英文部分
Amendola, A., Marsella, P., Bloisi, M., and et al. (2014) Ability of Two Commercially Available Assays (Abbott RealTime HIV1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) To Quantify Low HIV-1 RNA Levels (<1,000 Copies/Milliliter): Comparison with Clinical Samples and NIBSC Working Reagent for Nucleic Acid Testing Assays, Journal of Clinical Microbiology, 52, 6, 2019-2026.
Armstrong, D. (1995) The Rise of Surveillance Medicine, Sociology of Health and Illness, 17, 3, 393-404.
Bamford, L. (2017) Effective HIV Treatment Halts HIV Transmission among Homosexual Couples, Study Finds. The Kirby Institute, 25 July. Available at https://kirby.unsw.edu.au/news/effective-hiv-treatment-halts-hiv-transmission-among-homosexual-couples-study-finds.
Bavinton, B. R., Pinto, A. N., Phanuphak, N., et al. (2018) Viral Suppression and HIV Transmission in Serodiscordant Male Couples: An International, Prospective, Observational, Cohort Study, Lancet HIV, 5, 8, e438-e447. DOI: 10.1016/S2352-3018(18)30132–2.
Bernal, E., Gómez, J. M., Jarrín, I., et al. (2018) Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment, Journal of Acquired Immune Deficiency Syndromes, 78, 3, 329-337.
Bezabhe, W. M., Chalmers, L., Bereznicki, L. R., et al. (2014) Barriers and Facilitators of Adherence to Antiretroviral Drug Therapy and Retention in Care among Adult HIV-Positive Patients: A Qualitative Study from Ethiopia, PLoS One, 9, 5, e97353. DOI: 10.1371/journal.pone.0097353.
Biehl, J. (2007a) Pharmaceuticalization: AIDS Treatment and Global Health Politics, Anthropological Quarterly, 80, 4, 1083-1126.
Biehl, J. (2007b) Will to Live: AIDS Therapies and the Politics of Survival. New Jersey: Princeton University Press.
Boerner, H. (2016) How One Man Found Freedom Through an Undetectable HIV Viral Load. TheBody, 12 July. Available at https://www.thebody.com/article/ how-one-man-found-freedom-through-an-undetectable-.
Bourne, A., Dodds, C., Keogh, P., et al. (2009) Relative Safety II: Risk and Unprotected Anal Intercourse among Gay Men with Diagnosed HIV. London: Sigma Research. Available at http://www.sigmaresearch.org.uk/files/ report2009d.pdf.
British HIV Association & Expert Advisory Group on AIDS. (2013) Position Statement on the Use of Antiretroviral Therapy to Reduce HIV Transmission, January 2013: The British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA), HIV Medicine, 14, 259-262.
Clarke, A. E., Mamo, L., Fosket, J. R., et al. (Eds.). (2010) Biomedicalization: Technoscience, Health, and Illness in the U.S.. Durham: Duke University Press.
Clarke, A. and Shim, J. (2011) Medicalization and Biomedicalization Revisited: Technoscience and Transformations of Health, Illness and American Medicine. Handbook of the Sociology of Health, Illness and Healing, Part 3 (pp.173-199), Pescosolido, B., Martin, J., McLeod, J. and Rogers, A. (Eds.). New York: Springer.
Cohen, M. S., Chen, Y. Q., McCauley, M., et al. (2011) Prevention of HIV-1 Infection with Early Antiretroviral Therapy. New England Journal of Medicine, 365, 6, 493-505.
Connor, E. M., Sperling, R. S., Gelber, R., et al. (1994) Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment, New England Journal of Medicine, 331, 1173-1180.
Conrad, P. (2007) The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders. Johns Hopkins University Press.
Conrad, P. and Schneider, J. W. (1992) Deviance and Medicalization: From Badness to Sickness. (Expanded Edition) Philadelphia: Temple University Press.
Davis, M. (2015) After the Clinic? Researching Sexual Health Technology in Context, Culture, Health & Sexuality, 17, 4, 398-411.
Deleuze, G. (1992) What is a Dispositif. Michel Foucault, Philosopher, (pp. 159–168), Armstrong, T. J. (Trans. & Ed.). New York: Routledge.
Duran, D. (2014) Undetectable Is the New Negative?. POZ, 11 March. Available at https://www.poz.com/article/david-duran-25268-1687.
Ecks, S. (2005) Pharmaceutical Citizenship: Antidepressant Marketing and the Promise of Demarginalization in India. Anthropology and Medicine, 12, 239-254.
Eisinger, R. W., Dieffenbach, C. W., Fauci, A. S. (2019) HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable, JAMA. DOI:10.1001/jama.2018.21167.
European AIDS Clinical Society. (2012) Guidelines (version 6.1). Available at https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.
Evans, C., Bennett, J., Croston, M., et al. (2015) “In Reality, It is Complex and Difficult”: UK Nurses’ Perspectives on “Treatment as Prevention” within HIV Care, AIDS Care, 27, 6, 753-757.
Fairclough, N. (1995). Critical Discourse Analysis. Boston, MA: Addison Wesley.
Fairclough, N. (1992) Discourse and Social Change. Cambridge, UK: Polity Press.
Flowers, P. (2010) HIV Transitions: Consequences for Self in an Era of Medicalisation. HIV Treatment and Prevention Technologies in International Perspective, (pp. 109-125), Davis, M. and Squire, C. (Eds.). Basingstoke: Palgrave Macmillan.
Fosket, J. R. (2010). Breast Cancer Risk as Disease/Biomedicalizing Risk. Biomedicalization: Technoscience, Health, and Illness in the U.S., (pp. 331-352), Clarke, A. E., Mamo, L., Fosket, J. R., et al. (Eds.). Durham, NC: Duke University Press.
Foucault, M. (1991) Governmentality. The Foucault Effect: Studies in Governmentality, (pp. 87-104), Burchell, G., Gordon, C. and Miller, P. (Eds.). Hemel Hempstead: Harvester Wheatsheaf.
Foucault, M. (1984) Right of Death and Power over Life. The Foucault Reader, (pp. 258-272), Rabinow, P. (Ed.). New York: Pantheon.
Foucault, M. (1982) The Subject and Power. Michel Foucault: Beyond Structuralism and Hermeneutics, (pp. 208-226), Dreyfus, H. L. and Rabinow, P. (Eds.). The University of Chicago Press.
Foucault, M. (1981) The Order of Discourse. Untying the Text: A Poststructuralist Reader, (pp. 48-78), Young, R. (Ed.). Boston: Routledge and Kegan Paul.
Foucault, M. (1980) The Confession of the Flesh. Power/Knowledge: Selected Interviews and Other Writings, 1972-1977, (pp.194-196), Gordon, C. (Ed.). New York: Pantheon Books.
Foucault, M. (1978) The History of Sexuality, Volume 1: An Introduction. Hurley, R. (Trans.). New York: Pantheon Books.
Foucault, M. (1972) The Archaeology of Knowledge and the Discourse on Language. Sheridan, A. (Trans.) New York: Pantheon Books.
Freidson, E. (1970) Professional Dominance: The Social Structure of Medical Care. Chicago: Aldine.
Goffman, E. (1963) Stigma: Notes on the Management of Spoiled Identity. New York: Touchstone.
Goldhammer, H. et al. (2005) Beliefs about Viral Load, Sexual Positioning and Transmission Risk among HIV+ Men who Have Sex with Men (MSM): Shaping A Secondary Prevention Intervention. National HIV Prevention Conference, Atlanta, USA, presentation W0-D1201.
Greaves, D. (2000) The Creation of Partial Patients, Cambridge Quarterly of Health Care Ethics, 9, 23-27.
Grover, J. Z. (1988) AIDS: Keywords. AIDS: Cultural Analysis/Cultural Activism, (pp.17-30), Crimp, D. (Ed.). Cambridge, MA: The MIT Press.
Guzman, R., Buchbinder, S., Mansergh, G., et al. (2005) Communication of HIV viral load to make sexual risk decisions with serodiscordant partners among a diverse sample of men who have sex with men. National HIV Prevention Conference, Atlanta, USA, presentation TP-113.
Ho, D. D. (1995) Time to Hit HIV, Early and Hard, New England Journal of Medicine, 333, 7, 450-451. DOI: 10.1056/NEJM199508173330710.
Holt, M. (2015) Configuring the Users of New HIV-Prevention Technologies: The Case of HIV Pre-Exposure Prophylaxis, Culture, Health & Sexuality, 17, 4, 428-439.
Holtzman, C. W., Shea, J. A., Glanz, K., et al. (2015) Mapping Patient-Identified Barriers and Facilitators to Retention in HIV Care and Antiretroviral Therapy Adherence to Andersen’s Behavioral Model, AIDS Care, 27, 7, 817-828. DOI: 10.1080/09540121.
Illich, I. (1976) Medical Nemesis. New York: Pantheon.
INSIGHT START Study Group, Lundgren, J. D., Babiker, A. G., et al. (2015) Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, New England Journal of Medicine, 373, 9, 795-807.
Kaltwasser, J. (2017) Patients with Undetectable HIV Do Not Pose Transmission Risk. MD Magazine, 10 October. Available at https://www.mdmag.com/ medical-news/patients-with-undetectable-hiv-dont-pose-transmission-risk.
Kennedy, J. (2017) HIV-Positive Gay Men with Undetectable Viral Load Will Not Transmit Virus, Australian-Led Study Finds. ABC News, 25 July. Available at https://www.abc.net.au/news/2017-07-25/hiv-positive-men-taking-daily-medication-will-not-pass-virus-on/8742154.
Keogh, P. (2017) Embodied, Clinical and Pharmaceutical Uncertainty: People with HIV Anticipate the Feasibility of HIV Treatment as Prevention (TasP), Critical Public Health, 27, 1, 63-74.
Keogh, P. and Dodds, C. (2015) Pharmaceutical HIV Prevention Technologies in the UK: Six Domains for Social Science Research, AIDS Care, 27, 6, 796-803.
Kippax, S. (2013) Does TasP Spell the End of the Epidemic? 2nd International Conference for the Social Science and Humanities in HIV, Paris, session CS30.
Kippax, S. (2012) Effective HIV Prevention: The Indispensable Role of Social Science, Journal of the International AIDS Society, 15, 2, 17357. DOI: 10.7448/IAS.15.2.17357.
Kippax, S., and Stephenson, N. (2012) Beyond the Distinction Between Biomedical and Social Dimensions of HIV Prevention Through the Lens of a Social Public Health, American Journal of Public Health, 102, 5, 789-799. DOI: 10.2105/AJPH.2011.300594.
Kippax, S., Reis, E., and de Wit, J. (2011) Two Sides to the HIV Prevention Coin: Efficacy and Effectiveness, AIDS Education and Prevention, 23, 5, 393-396.
Kippax, S., and Race, K. (2003). Sustaining Safe Practice: Twenty Years On, Social Science & Medicine, 57, 1-12.
Klawiter, M. (2002) Risk, Prevention and the Breast Cancer Continuum: The NCI, the FDA, Health Activism and the Pharmaceutical Industry, History and Technology, 18, 4, 309-353.
Lambert-Niclot, S., Tubiana, R., Beaudoux, C., et al. (2012) Detection of HIV-1 RNA in Seminal Plasma Samples from Treated Patients with Undetectable HIV-1 RNA in Blood Plasma on a 2002-2011 Survey, AIDS, 26, 971-975.
Lemke, T. (2011) Biopolitics: An Advanced Introduction. New York: NYU Press.
Lessard, D., Toupin, I., Engler, K., et al. (2018) HIV-Positive Patients’ Perceptions of Antiretroviral Therapy Adherence in Relation to Subjective Time: Imprinting, Domino Effects, and Future Shadowing, Journal of the International Association of Providers of AIDS Care, 17, 1-8.
Li, Chia-Lin. (2017) From Treatable to Undetectable: Bio-political Implications of HIV/AIDS “Treatment as Prevention”. Imagining the Possibilities of the University and Civil Society from East Asia, (pp. 45-58), Ishii, T. and Ishikawa, M. (Eds.). Tokyo: IHS.
Li, Chia-Lin. (2011) The Uses of “Men who have Sex with Men” in Taiwan’s Official AIDS Discourse. MA Thesis, Department of English, National Central University.
Lo, Yi-Chun, Chuang, Jen-Hsiang, Huang, Yen-Fang, et al. (2020) GBD 2017 and HIV Estimates for Taiwan, Lancet HIV, 7, 4, e224. DOI: 10.1016/S2352-3018(20)30040-0.
Lupton, D. (1993) Risk as Moral Danger: The Social and Political Functions of Risk Discourse in Public Health, International Journal of Health Services, 23, 3, 425-435.
Lupton, D. (1997) Foucault and the Medicalization Critique. Foucault: Health and Medicine, (pp. 94-112), Peterson, A. and Bunton, R. (Eds.). London: Routledge.
Lupton, D. (2013) Risk. London: Routledge.
Markley, J. (2018) Is Undetectable the New Negative?. Positive, 9 July. Available at https://positiveresourceconnection.org/2018/07/09/is-undetectable-the-new-negative/.
Marsh, K., Eaton, J. W., Mahy, M., et al. (2019) Global, Regional and Country-Level 90-90-90 Estimates for 2018: Assessing Progress towards the 2020 Target, AIDS, 33 (Suppl 3), 213-226.
McCoy, L. (2009) Time, Self and the Medication Day: A Closer Look at the Everyday Work of Adherence, Sociology of Health and Illness, 31, 1, 128-146.
McCray, E. (2019) Dear Health Department and CBO Grantees. Centers for Disease Control and Prevention, 30 August. Available at https://docs.wixstatic.com/ugd/ de0404_966c29f826d4481abf8bba0690bdd439.pdf. Retrieved 1 October, 2019.
McCray, E., and Mermin, J. (2017) National Gay Men's HIV/AIDS Awareness Day. Centers for Disease Control and Prevention, 27 September. Available at https://www.cdc.gov/nchhstp/dear_colleague/2017/dcl-092717-National-Gay-Mens-HIV-AIDS-Awareness-Day.html. Retrieved 8 October, 2017.
Meyers, T. (2013) The Clinic and Elsewhere: Addiction, Adolescents, and the Afterlife of Therapy. Seattle, WA: University of Washington Press.
Montaner, J. S., Lima, V. D., Barrios, R., et al. (2010) Association of Highly Active Antiretroviral Therapy Coverage, Population Viral Load, and Yearly New HIV Diagnoses in British Columbia, Canada: a Population-Based Study, Lancet, 376, 532-539.
Moyer, E. (2015) The Anthropology of Life After AIDS: Epistemological Continuities in the Age of Antiretroviral Treatment, Annual Review of Anthropology, 44, 259-275.
Moyer, E. and Hardon, A. (2014) A Disease Unlike Any Other? Why HIV Remains Exceptional in the Age of Treatment, Medical Anthropology, 33, 4, 263-269.
Mykhalovskiy, E. (2010) Integrating HIV Treatment and Prevention: Shifts in Community-Based Organising and Biopolitics in the Canadian Context. HIV Treatment and Prevention Technologies in International Perspective, (pp. 61-86), Davis, M. and Squire, C. (Eds.). Basingstoke: Palgrave Macmillan.
Mykhalovskiy, E., McCoy, L., and Bresalier, M. (2004) Compliance/Adherence, HIV, and the Critique of Medical Power, Social Theory & Health, 2, 4, 315-340.
Nguyen, V-K. (2004) Antiretroviral Globalism, Biopolitics, and Therapeutic Citizenship. Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems, (pp. 124-144), Ong, Aihwa and Collier, S. J. (Eds.). Malden, MA: Blackwell Publication.
Nguyen, V-K., Ako, C. Y., Niamba, P., et al. (2007) Adherence as Therapeutic Citizenship: Impact of the History of Access to Antiretroviral Drugs on Adherence to Treatment, AIDS, 21 (suppl. 5), S31-S35.
Nguyen, V-K. (2010) Introduction: Côte-d’Ivoire and Triage in the Time of AIDS; Life Itself: Triage and Therapeutic Citizenship. The Republic of Therapy: Triage and Sovereignty in West Africa’s Time of AIDS, (pp. 1-13; 89-109), Durham, NC: Duke University Press.
Nguyen, V-K., Bajos, N., Dubois-Arber, F., et al. (2011) Remedicalizing an Epidemic: From HIV Treatment as Prevention to HIV Treatment is Prevention, AIDS, 25, 3, 291-293.
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2012) Guidelines For the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ ContentFiles/Adultand AdolescentGL.pdf.
Patton, C. (2011) Rights Language and HIV Treatment: Universal Care or Population Control?, Rhetoric Society Quarterly, 41, 3, 250-266.
Patton, C. (1990) Inventing AIDS. New York and London: Routledge.
Persson, A. (2016) ‘The World Has Changed’: Pharmaceutical Citizenship and the Reimagining of Serodiscordant Sexuality among Couples with Mixed HIV Status in Australia, Sociology of Health and Illness, 38, 3, 380-395.
Persson, A. (2015) Significant Ambivalence: Perspectives of Australian HIV Service Providers on Universal Treatment-as-Prevention (TasP) for Serodiscordant Couples, Critical Public Health, 25, 2, 153-164.
Persson, A. (2013) Noninfectious Corporealities: Tensions in the Biomedical Era of HIV Normalisation, Sociology of Health and Illness, 35, 7, 1065-1079.
Persson, A., Newman, C. E., Mao, L., and de Wit, J. (2016) On the Margins of Pharmaceutical Citizenship: Not Taking HIV Medication in the “Treatment Revolution” Era, Medical Anthropology Quarterly, 30, 3, 359-377.
Rabinow, P., and Rose, N. (2006) Biopower Today, BioSocieties, 1, 2, 195-217.
Race, K. (2008) The Use of Pleasure in Harm Reduction: Perspectives from the History of Sexuality, International Journal of Drug Policy, 19, 5, 417-423.
Race, K. (2003) Revaluation of Risk among Gay Men, AIDS Education and Prevention, 15, 4, 369-381.
Rodger, A. J., Cambiano, V., Bruun, T., et al. (2019) Risk of HIV Transmission through Condomless Sex in Serodifferent Gay Couples with the HIV-Positive Partner Taking Suppressive Antiretroviral Therapy (PARTNER): Final Results of a Multicentre, Prospective, Observational Study, The Lancet. DOI: 10.1016/S0140-6736(19)30418-0.
Rodger, A. J., Cambiano, V., Bruun, T., et al. (2016) Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy, JAMA, 316, 2, 171-181. DOI:10.1001/jama.2016.5148.
Rodger, A. J., Bruun, T., Vernazza, P., et al. (2013) Further Research Needed to Support a Policy of Antiretroviral Therapy as an HIV Prevention Initiative, Antiviral Therapy, 18, 3, 285-287.
Rose, N. (2007) The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. New Jersey: Princeton University Press.
Samuel, K. (2019) U=U is a Human Rights Issue. Aidsmap, 12 March. Available at http://www.aidsmap.com/page/3466390/#item3466392.
Sangaramoorthy, T. (2012) Treating the Numbers: HIV/AIDS Surveillance, Subjectivity, and Risk, Medical Anthropology, 31, 4, 292-309.
Simmons, P. (2000) When Paradigms Fall: the Demise of “Hit Hard, Hit Early”, Research initiative, treatment action: RITA, 5, 5, 11-12.
Squire, C. (2010) Being Naturalised, Being Left Behind: The HIV Citizen in the Era of Treatment Possibility, Critical Public Health, 20, 4, 401-427.
Stimson, G. V. (1974) Obeying Doctor’s Orders: A View from the Other Side, Social Science & Medicine, 8, 2, 97-104.
TEMPRANO ANRS Study Group, Danel, C., Moh, R., et al. (2015) A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa, New England Journal of Medicine, 373, 9, 808-822. DOI: 10.1056/NEJMoa1507198.
Timmermans, S. (2010) Evidence-Based Medicine: Sociological Explorations. Handbook of Medical Sociology 6th edition, (pp.309-337), Bird, C. E., Conrad, P., Fremont, A. M., and Timmermans, S. (Eds.). Nashville: Vanderbilt University Press.
Treichler, P. A. (1988) AIDS, Homophobia and Biomedical Discourse: An Epidemic of Signification. AIDS: Cultural Analysis/Cultural Activism, (pp. 31-71), Crimp, D. (Ed.). Cambridge, MA: The MIT Press.
Trostle, J. A. (1988) Medical Compliance as An Ideology, Social Science & Medicine, 27, 12, 1299-1308.
Trostle, J. A., Hauser, W. A., and Susser, I. S. (1983) The Logic of Noncompliance: Management of Epilepsy from the Patient’s Point of View, Culture, Medicine and Psychiatry, 7, 1, 35-56.
UNAIDS. (2018) Undetectable=Untransmittable: Public Health and HIV Viral Load Suppression. Joint United Nations Programme on HIV/AIDS (UNAIDS). Available at https://www.unaids.org/sites/default/files/media_asset/ undetectable -untransmittable_en.pdf.
UNAIDS. (2014) 90-90-90: An Ambitious Treatment Target to Help End the AIDS Epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS). Available at http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf.
Van de Ven, P., Mao, L., Fogarty, A., et al. (2005) Undetectable Viral Load is Associated with Sexual Risk Taking in HIV Serodiscordant Gay Couples in Sydney, AIDS, 19, 2, 179-184.
Vernazza, P., and Bernard, E. (2016) HIV is Not Transmitted Under Fully Suppressive Therapy: The Swiss Statement–Eight Years Later, Swiss Medical Weekly, 146:w14246. DOI: 10.4414/smw.2016.14246.
Vernazza, P. (2009) The Debate Continues: Does ‘Undetectable’ Mean ‘Uninfectious’?, HIV Therapy, 3, 2, 113-116.
Vernazza, P., Hirschel, B., Bernasconi, E., and Flepp, M. (2008a) Les personnes seropositives ne souffrant d’aucune autre MST et suivant un traitment antiretroviral efficie ne transmettent pas le VIH par voie sexuelle, Bull Med Suisses, 89, 165-169.
Vernazza, P., Hirschel, B., Bernasconi, E., and Flepp, M. (2008b) HIV Transmission Under Highly Active Antiretroviral Therapy, The Lancet, 372, 9652, 1806-1807.
WHO. (2017) Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy. World Health Organization. Available at https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en/.
WHO. (2016) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, second edition. World Health Organization. Available at https:// apps.who.int/iris/handle/10665/208825.
WHO. (2015a) Policy Brief: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: What’s New. World Health Organization. Available at https://apps.who.int/iris/handle/10665/198064.
WHO. (2015b) Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization. Available at https://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/.
WHO. (2012a) Programmatic Update: Antiretroviral Treatment as Prevention (TASP) for HIV and TB. World Health Organization. Available at https://www.who.int/ hiv/pub/mtct/programmatic_update_tasp/en/.
WHO. (2012b) Guidance on Couples HIV Testing and Counselling, Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples: Recommendations for a Public Health Approach. World Health Organization. Available at http://apps.who.int/iris/bitstream/10665/44646/1/ 9789241501972_ eng.pdf.
WHO and UNAIDS. (2011) Groundbreaking Trial Results Confirm HIV Treatment Prevents Transmission of HIV. World Health Organization, 12 May. Available at https://www.who.int/hiv/mediacentre/trial_results/en/. Retrieved 24 March, 2019.
Williams, S. J., Martin, P., and Gabe, J. (2011) The Pharmaceuticalisation of Society? A Framework for Analysis, Sociology of Health and Illness, 33, 5, 710-725.
Wilson, A. J., Morgan, E. R., Booth, M., et al. (2017) What Is a Vector?. Philosophical Transactions of the Royal Society of London Series B Biological Sciences, 372, 1719: 20160085. DOI: 10.1098/rstb.2016.0085.
Young, I., Davis, M., Flowers, P., et al. (2019) Navigating HIV citizenship: identities, risks and biological citizenship in the treatment as prevention era. Health, Risk & Society, 21, 1-2, 1-16.
Young, R. (1981) Post-structuralism: An introduction. Untying the Text: A Poststructuralist Reader, (pp. 1-28), Young, R. (Ed.). Boston: Routledge and Kegan Paul.
Zola, I. K. (1972) Medicine as an Institution of Social Control, Sociological Review, 20, 487-504.
Zola, I. K. (1981) Structural Constraints in the Doctor–Patient Relationship: the Case of Non-Compliance. The Relevance of Social Science for Medicine, (pp. 241-252), Eisenberg, L., and Kleinman, A. (Eds.). Boston, MA: D. Reidel Publishing.
(二)中文部分
丁志音、陳欣欣，2000。〈預防為最上策—民眾的愛滋病性病防治信念與對保險套的看法〉。《中華公共衛生雜誌》，19卷3期，頁180-191。
王增勇，2003。〈照顧與控制之間—以「個案管理」在社工場域的論述實踐為例〉。《台灣社會研究季刊》，51期，頁143-183。
行政院衛生署，2011。《愛滋防治第五期五年計畫》。台北市：行政院衛生署。
行政院衛生署疾病管制局，2010。《愛滋病檢驗及治療指引》(第三版)。台北市：行政院衛生署疾病管制局。
朱慧真，2014。《影響愛滋感染者服用抗病毒藥物達到病毒抑制之相關因素》。國立成功大學護理學系碩士論文，台南市。
呂妍庭，2019。〈強化愛滋患者服藥動力 友善藥局成助力〉。11月28日，中時電子報。檢自：https://www.chinatimes.com/realtimenews/20191128003973- 260405?chdtv。
李育霖、羅一鈞、洪健清，2018。〈臺灣愛滋病毒感染者抗愛滋病毒藥物的治療建議〉。《愛之關懷》，104期，頁4-38。
李佳霖，2016。〈愛滋罪罰化之社會衝擊的回顧與省思〉。《愛之關懷》，97期，頁29-36。
李佳霖，2013。〈治理「性／病」：台灣愛滋防治的性治理〉。發表於2013年台灣社會研究學會研討會年會。台北市：世新大學。
李素芬、林育蕙、潘忠煜，2013。〈病人對愛滋病個案管理計畫之依循度與生物指標及性行為之相關性〉。《台灣醫學》，17卷1期，頁1-8。
邱珠敏、丁志音，2010。〈「愛滋病個案管理師計畫」對於個案行為與健康狀況之影響〉。《臺灣公共衛生雜誌》，29卷4期，頁299-313。
邱珠敏、黃彥芳、楊靖慧等，2010。〈他山之石—由美國愛滋病個案管理制度談台灣「愛滋病個案管理師計畫」〉。《台灣衛誌》，29卷1期，頁1-7。
邱伊翎，2006。《一個也不能少：台灣愛滋篩檢的風險治理》。國立清華大學社會學研究所碩士論文，新竹市。
杜思誠，2008。《高風險的性？從男同志轟趴參與者的性實作檢視「多重性伴侶」的愛滋風險論述》。國立臺灣大學社會學研究所碩士論文，台北市。
林德宇、王甯祺，2019。〈未曾接觸過抗病毒藥物之愛滋病毒感染者病毒抗藥性趨勢〉。《感染控制雜誌》，29卷6期，頁307-316。
林宜瑩，2018。〈反歧視 台北首間愛滋友善藥局〉。1月17日，台灣教會公報。檢自：https://tcnn.org.tw/archives/31565。
林宜慧，2015。〈從民間立場談人類免疫缺乏病毒傳染防治及感染者權益保障條例：成果及影響〉。《愛之關懷》，90期，頁26-34。
林文源，2014。《看不見的行動能力：從行動者網絡到位移理論》。台北市：中央研究院社會學研究所。
林宜君，2011。〈我要如何幫自己?~淺談服藥順從〉。5月30日，檢自：https://www.hhat.org/info/27?tid=3。
金毓慶，2004。〈影響愛滋感染者服藥遵從行為之因素分析〉。《臺灣社會工作學刊》，1期，頁74-107。
洪健清，2018。〈台灣現有抗愛滋病毒治療藥物與抗藥性簡介〉。《防癆雜誌》，夏季號，頁14-23。
胡凱評，2016。《影響愛滋感染者服藥意願之因素初探：質性研究》。國立台灣大學健康政策與管理研究所碩士論文，台北市。
范順淵，2013。《2007年擴大男同志愛滋篩檢政策之分析》。世新大學性別研究所碩士論文，台北市。
柯乃熒、劉曉穎、賴霈妤等，2006。〈HIV個案管理模式及其成效評估〉。《感染控制雜誌》，16卷4期，頁237-245。
紀秉宗，2010。《愛滋病個案管理計畫效果研究》。國立台灣師範大學健康促進與衛生教育學系碩士論文，台北市。
連勝祥、羅國暐，2019。〈開心，不開心？〉。4月7日，檢自：https://hivstorymedia.org/?p=5067。
陳偉婷，2019。〈愛滋防疫見效 108年新發人數創10年新低〉。11月29日，檢自：https://www.cna.com.tw/news/firstnews/201911290215.aspx。
陳潔，2018。〈不靠基因編輯！台灣3萬名愛滋感染者，可結婚、生健康小孩〉。12月1日，天下雜誌電子版。檢自：https://www.cw.com.tw/article/article.action? id=5093111&fbclid=IwAR1yHVseF1S1vVLyk8zVY7FGFKrSLZxXA5JbgHYc8mmWN3GvI5nYDu_MJ5Y。
陳冠州、蔡宏津、張淑媛，2018。〈成人愛滋病毒感染者之病毒量、CD4淋巴球數及相關檢驗指引〉。《愛之關懷》，105期，頁6-11。
陳嘉新，2017。〈生命政治與社會偏差：初探臺灣的鴉片類藥物治理史〉。王文基、劉士永編《東亞醫療史：殖民、性別與現代性》，頁279-301。台北市：聯經。
陳馨傑，2011。《男同志HIV感染者的帶病生涯與自我照顧》。國立陽明大學衛生福利研究所碩士論文，台北市。
陳佳樺，2002。《愛滋病雞尾酒療法遵從性的探索：感染者的主觀經驗及因應方式》。國立台灣大學衛生政策與管理研究所碩士論文，台北市。
陳茂源，1996。〈愛滋病毒感染之藥物治療—1996年6月〉。《疫情報導》，12卷9期，頁285-291。
倪炎元，2012。〈批判論述分析的定位爭議及其應用問題：以NormanFairclough分析途徑為例的探討〉。《新聞學研究》，110期，頁1-42。
徐森杰，2012。〈為臺灣愛滋病個案管理制度把脈—談社會、醫療暨公衛個案管理模式之展望〉。《社區發展季刊》，137期，頁241-249。
徐美苓、熊培伶、賴若函等，2011。〈是減害還是加害？愛滋新聞論述中的毒癮者框架〉。《台灣社會研究季刊》，81期，頁79-128。
梁元安，2017。《「我是H」：穿越在多重治理網絡間的行動和枷鎖》。國立清華大學社會學研究所碩士論文，新竹市。
莊登閔、宋麗玉，2013。〈臺灣愛滋感染者權能增強影響因素之研究〉。《臺大社會工作學刊》，28期，頁47-91。
莊佳蓁，2008。《台灣孕婦對愛滋產前篩檢自主權之實證研究》。國立陽明大學公共衛生研究所碩士論文，台北市。
彭安婷，2019。〈【新竹快訊】診斷愛滋即刻服藥—就「藥」你方便〉。臺大醫院健康電子報，138期。檢自：https://epaper.ntuh.gov.tw/health/201905/story_ 3.html。
傅柯（Foucault, M.），2016。〈自我技術〉。汪民安編《自我技術：福柯文選Ⅲ》，頁51-104。北京市：北京大學出版社。
傅柯（Foucault, M.），2011。《生命政治的誕生》。（莫偉民、趙偉譯）。上海市：上海人民出版社。
傅柯（Foucault, M.），2010。《安全、領土與人口》（錢翰、陳曉徑譯）。上海市：上海人民出版社。
傅柯（Foucault, M.），2010。《必須保衛社會》（錢翰譯）。上海市：上海人民出版社。
傅凱群，2018。《愛滋感染者取得與服用抗愛滋藥物的建制民族誌研究》。國立陽明大學衛生福利研究所碩士論文，台北市。
傅大為，2017。〈「醫療化」論點的當代多元演化，與來自性別與社會研究的商榷〉。王文基、劉士永編《東亞醫療史：殖民、性別與現代性》，頁191-221。台北市：聯經。
黃彥芳、楊志元、李佳琪等，2017。《愛滋疫情趨勢估計及防治成效評估》。衛生福利部疾病管制署一0六年度科技研究發展計畫（計畫編號： MOHW106-CDC-C-315-000125）。
黃道明，2014。〈列管制度下的醫療治理：「人類免疫缺乏病毒傳染防治及感染者權益保障條例」與新道德威權〉。《台灣社會研究季刊》，94期，頁107-146。
黃薰瑩、楊玉玟、黃貴莉等，2012。〈「100 年度男男間性行為（MSM）特定場域推廣使用保險套先驅工作計畫」後續分析〉。《疫情報導》，28卷8期，頁135-142。
游美惠，2000。〈內容分析、文本分析與論述分析在社會研究的運用〉。《調查研究》，8期，頁5-42。
感染誌，2019。〈呼籲支持國際共識【U=U】測不到等於不具感染力，真人實事改編首部女性愛滋微電影，見證U=U幸福曙光〉。11月25日，檢自：https://hiv-story.org/2019/11/25/2019tyhpuu/。
楊絡懸、詹雅婷、張嘉晏，2019。〈急診醫大喊「這人有H」曝身分…診室全聽到！羅一鈞：理解最重要〉。5月4日，檢自：https://www.ettoday.net/news/ 20190504/1427273.htm。
潘柏翰，2015。《愛滋病個案管理師管理技巧及其與感染者關係初探—以輔導感染者自我健康為例》。國立台灣大學健康政策與管理研究所碩士論文，台北市。
衛生福利部，2016。《愛滋防治第六期五年計畫》。台北市：衛生福利部。
衛生福利部，2014。《愛滋防治第五期五年計畫》(修訂版)。台北市：衛生福利部。
衛生福利部，2013。〈疾管局自102年7月1日起調降11種愛滋治療藥物藥價〉。6月28日，檢自：https://www.mohw.gov.tw/cp-3213-23236-1.html。
衛生福利部疾病管制署，2017。〈疾管署新增愛滋指定醫院及指定藥局，感染者就醫領藥更方便〉。1月17日，檢自：https://www.cdc.gov.tw/Category/ ListContent/Hh094B49-DRwe2RR4eFfrQ?uaId=S5m3noV0omnruhGe6cJIFQ。
衛生福利部疾病管制署，2016。〈愛滋用藥大利多，六月起與先進國家齊步〉。5月3日，檢自：https://www.cdc.gov.tw/Category/ListContent/ TKG- 8nvtp3Y1fHxeMxWJ1Q?uaid=aX0bX6S3Qmd89kfK9xSJKw。
衛生福利部疾病管制署，2014。《愛人愛己同舟共濟：愛滋病防治專書》。台北市：衛生福利部疾病管制署。
衛生福利部疾病管制署，2013。《愛滋病檢驗及治療指引》(第四版)。台北市：衛生福利部疾病管制署。
蔡季君，2006。《愛滋病防治模式的運作—從強效抗愛滋治療HAART相關的整體醫療照顧，到危險族群的介入》。高雄醫學大學醫學研究所博士論文，高雄市。
賴穎萱，2018。〈淺談HIV治療利器—複方單錠藥物〉。《彰基藥訊》，26卷1期，頁5-8。
謝佳吟、賴怡因、陳嬿今等，2018。〈預測愛滋感染者決定服藥之服藥準備度的最佳臨床切點〉。《護理雜誌》，65卷2期，頁54-63。
羅一鈞，2016。《心之谷：羅一鈞醫生給愛滋感染者和感染者親友的溫暖叮嚀》。台北市：貓頭鷹。
羅一鈞，2011。〈台灣新增列的HIV第一線用藥(2)—Isentress(宜昇瑞)〉。7月21日，檢自：http://heartvalley.blogspot.com/2011/07/hiv2isentress.html。
|